Inhalation Profiles in Asthmatics and COPD Patients: Reproducibility and Effect of Instruction
- 1 June 2003
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Aerosol Medicine
- Vol. 16 (2), 131-141
- https://doi.org/10.1089/089426803321919898
Abstract
Turbuhaler and Salbutamol-Diskus produce therapeutic doses at peak inspiratory flow (PIF) of >30 L/min. However, the optimum flow for Fluticasone-Diskus and Turbuhaler, in terms of total emitted dose and fine particle mass, is >60 L/min. The Turbuhaler achieved a higher output at this flow, as compared to Diskus. For pMDI 25 < PIF < 90 L/min, an actuation time of 0.0-0.2 sec is optimal. The aim of this study was to examine the incidence of optimum inhalation profiles, the effect of instruction, reproducibility, and the relationship between inhalation profiles and patient characteristics in stable asthmatics and mild/moderate/severe COPD patients. For each device, triplicate inhalation profiles were recorded during 6 sessions in a 10-week period. All patients achieved PIF > 30 L/min using Diskus. After instruction, all Diskus inhalations were performed with >60 L/min, except 7% of the inhalations of the severe COPD patients. At least 95% of the Turbuhaler inhalations was also performed with the minimum flow; however, 19% of the inhalations of the severe COPD patients were not optimally performed. The hand-lung coordination was inadequate in 40% of pMDI inhalation profiles, and 80% was performed with a too high flow. The reproducibility of PIF of both dry powder inhalers (DPIs) was very high (coefficient of variation = 4-10%). The reproducibility of the pMDI variables was lower (coefficient of variation = 9-18%). The major lung function variables predictive for PIF(diskus) and PIF(turbuhaler) were maximal inspiratory mouth pressure (MIP), PIF, and inspiratory capacity. No significant predictive lung function variables for PIF(pMDI) were found. Most patients performed reproducible optimum inhalation profiles through Diskus and Turbuhaler. However, in the severe COPD group, 7-19% of the patients were not able to generate the optimum flows through the DPIs. For these patients, a flow-independent aerosol delivery system might be more suitable. The majority of patients were using the pMDI incorrectly. Instruction had no effect. So, we concluded that the pMDI should not be used in these patient groups because of the coordination problems.Keywords
This publication has 29 references indexed in Scilit:
- Review of therapeutically equivalent alternatives to short acting beta 2 adrenoceptor agonists delivered via chlorofluorocarbon-containing inhalersThorax, 1999
- Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic childrenEuropean Respiratory Journal, 1998
- Delivery Devices for Inhaled Asthma MedicationClinical Immunotherapeutics, 1996
- Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers Part 2: Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalersInternational Journal of Pharmaceutics, 1996
- The DiskusTM: A New Multi-Dose Powder Device – Efficacy and Comparison with TurbuhalerTMJournal of Aerosol Medicine, 1995
- The Relationship Between Powder Inhaler Resistance and Peak Inspiratory Conditions in Healthy Volunteers — Implications for In Vitro TestingJournal of Aerosol Medicine, 1993
- Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique.Thorax, 1991
- RISK FACTORS FOR INADEQUATE USE OF PRESSURIZED AEROSOL INHALERSJournal of Clinical Pharmacy & Therapeutics, 1988
- Principles of Aerosol TherapySocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1982